Sorry, your browser does not support JavaScript!
For the latest updates on Gilead’s ongoing response to COVID-19, please
click here
.
×
Investor Relations
Contact Us
KiteKonnect®
About Us
Our Mission
Our Story
Therapeutic Areas
Leadership
Kite Locations
Grants
Science & Medicine
Our Technology
Our Therapies
Pipeline
Trials & Expanded Access
External Research Program (ERP)
Newsroom
Newsroom
Media Kit
Press Releases
Company Statements
Careers
Now Hiring
Careers at Kite
Early Talent Programs at Kite
Culture & Benefits
Utility
Contact Us
KiteKonnect®
BACK TO MAIN MENU
Company Statements
Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma
Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma
Kite Announces U.S. FDA Clearance of Investigational
Investor Relations
Toggle Inner Dropdown
BACK TO MAIN MENU
Google.com
Compliance Program
Gilead Ethics and Code of Conduct
US Disclosures
California
